About Immutrix Therapeutics
Immutrix Therapeutics is a company based in Rapid City (United States) founded in 2009 by Carol Rae. Immutrix Therapeutics has raised $14.02 million across 6 funding rounds. Immutrix Therapeutics offers products and services including Blood-Cleansing Device and Extracorporeal System. Immutrix Therapeutics operates in a competitive market with competitors including Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others.
- Headquarter Rapid City, United States
- Founders Carol Rae
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Immutrix Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.02 M (USD)
in 6 rounds
-
Latest Funding Round
$480 K (USD), Debt – Conventional
Sep 18, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immutrix Therapeutics
Immutrix Therapeutics offers a comprehensive portfolio of products and services, including Blood-Cleansing Device and Extracorporeal System.
Device removes harmful molecules from blood to treat medical conditions.
System modulates blood components for rapid-response disease treatment.
People of Immutrix Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Immutrix Therapeutics
Immutrix Therapeutics has successfully raised a total of $14.02M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $480 thousand completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Immutrix Therapeutics
Investment portfolio details for Immutrix Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immutrix Therapeutics
Detailed financials for Immutrix Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immutrix Therapeutics Comparisons
Peer comparison for Immutrix Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immutrix Therapeutics
Immutrix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hematology products and solutions are provided for medical applications.
|
|
| Locked | Locked | Locked |
Catheters for venous clot management and removal are developed.
|
|
| Locked | Locked | Locked |
Magnetic therapy is developed to treat blood-borne diseases.
|
|
| Locked | Locked | Locked |
Develops and manufactures hemostatic products for surgical bleeding control and patient care.
|
|
| Locked | Locked | Locked |
Blood filtration therapy for severe sepsis is developed.
|
Detailed competitors of Immutrix Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immutrix Therapeutics
Complete news archive for Immutrix Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immutrix Therapeutics
Immutrix Therapeutics was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Immutrix Therapeutics is headquartered in Rapid City, United States. It is registered at Rapid City, South Dakota, United States.
Carol Rae is the current CEO of Immutrix Therapeutics. They have also founded this company.
Immutrix Therapeutics is a funded company, having raised a total of $14.02M across 6 funding rounds to date.
Immutrix Therapeutics develops blood cleansing treatment device. It removes inflammatory mediators and toxins from blood using proprietary adsorbents and smart hollow fiber membranes. It cleanses whole blood to modulate and sequester molecules from circulation. It targets and binds molecules to treat a broad range of medical conditions.
Immutrix Therapeutics's top competitors include Haemonetics, Vetex Medical and MediSieve.
Immutrix Therapeutics offers Blood-Cleansing Device and Extracorporeal System.